Vericel Corporation (VCEL)
USD 42.06
(-3.29%)
USD 42.06
(-3.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 127.7 Million USD | 58.19% |
| 2022 | 80.73 Million USD | 10.22% |
| 2021 | 73.24 Million USD | 2.66% |
| 2020 | 71.34 Million USD | 69.28% |
| 2019 | 42.14 Million USD | 156.09% |
| 2018 | 16.45 Million USD | -48.63% |
| 2017 | 32.03 Million USD | 34.11% |
| 2016 | 23.88 Million USD | 96.15% |
| 2015 | 12.17 Million USD | 2.02% |
| 2014 | 11.93 Million USD | 124.36% |
| 2013 | 5.32 Million USD | -6.07% |
| 2012 | 5.66 Million USD | -72.65% |
| 2011 | 20.71 Million USD | -30.75% |
| 2010 | 29.9 Million USD | 1401.26% |
| 2009 | 1.99 Million USD | -30.91% |
| 2008 | 2.88 Million USD | -37.29% |
| 2007 | 4.59 Million USD | 81.06% |
| 2006 | 2.53 Million USD | 192.17% |
| 2005 | 869 Thousand USD | 55.73% |
| 2004 | 558 Thousand USD | -3.79% |
| 2003 | 580 Thousand USD | -22.67% |
| 2002 | 750 Thousand USD | -25.82% |
| 2001 | 1.01 Million USD | 0.9% |
| 2000 | 1 Million USD | -2.62% |
| 1999 | 1.02 Million USD | -32.66% |
| 1998 | 1.52 Million USD | -15.11% |
| 1997 | 1.8 Million USD | -95.01% |
| 1996 | 36.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 122.76 Million USD | -3.87% |
| 2024 Q2 | 133.86 Million USD | 9.04% |
| 2023 Q2 | 111.78 Million USD | 57.18% |
| 2023 FY | 127.7 Million USD | 58.19% |
| 2023 Q1 | 71.11 Million USD | -11.91% |
| 2023 Q3 | 113.74 Million USD | 1.76% |
| 2023 Q4 | 127.7 Million USD | 12.27% |
| 2022 Q3 | 70.18 Million USD | 0.26% |
| 2022 Q1 | 67.8 Million USD | -7.43% |
| 2022 Q4 | 80.73 Million USD | 15.03% |
| 2022 FY | 80.73 Million USD | 10.22% |
| 2022 Q2 | 69.99 Million USD | 3.24% |
| 2021 Q4 | 73.24 Million USD | 8.73% |
| 2021 FY | 73.24 Million USD | 2.66% |
| 2021 Q3 | 67.36 Million USD | -4.93% |
| 2021 Q2 | 70.85 Million USD | -0.56% |
| 2021 Q1 | 71.25 Million USD | -0.13% |
| 2020 FY | 71.34 Million USD | 69.28% |
| 2020 Q1 | 42.43 Million USD | 0.69% |
| 2020 Q2 | 39.09 Million USD | -7.88% |
| 2020 Q4 | 71.34 Million USD | 66.41% |
| 2020 Q3 | 42.87 Million USD | 9.67% |
| 2019 Q3 | 40.53 Million USD | 8.72% |
| 2019 Q4 | 42.14 Million USD | 3.97% |
| 2019 FY | 42.14 Million USD | 156.09% |
| 2019 Q1 | 38.17 Million USD | 131.95% |
| 2019 Q2 | 37.28 Million USD | -2.33% |
| 2018 Q4 | 16.45 Million USD | -45.12% |
| 2018 FY | 16.45 Million USD | -48.63% |
| 2018 Q1 | 31.47 Million USD | -1.76% |
| 2018 Q2 | 31.59 Million USD | 0.38% |
| 2018 Q3 | 29.98 Million USD | -5.09% |
| 2017 Q2 | 22.56 Million USD | -10.06% |
| 2017 Q3 | 23.54 Million USD | 4.34% |
| 2017 Q1 | 25.08 Million USD | 5.0% |
| 2017 FY | 32.03 Million USD | 34.11% |
| 2017 Q4 | 32.03 Million USD | 36.09% |
| 2016 Q1 | 13.83 Million USD | 13.56% |
| 2016 Q4 | 23.88 Million USD | 43.66% |
| 2016 Q3 | 16.62 Million USD | 34.9% |
| 2016 Q2 | 12.32 Million USD | -10.87% |
| 2016 FY | 23.88 Million USD | 96.15% |
| 2015 FY | 12.17 Million USD | 2.02% |
| 2015 Q2 | 10.97 Million USD | -14.19% |
| 2015 Q3 | 9.4 Million USD | -14.28% |
| 2015 Q1 | 12.79 Million USD | 7.14% |
| 2015 Q4 | 12.17 Million USD | 29.45% |
| 2014 Q1 | 6.1 Million USD | 14.81% |
| 2014 FY | 11.93 Million USD | 124.36% |
| 2014 Q4 | 11.93 Million USD | -5.23% |
| 2014 Q3 | 12.59 Million USD | -26.12% |
| 2014 Q2 | 17.05 Million USD | 179.11% |
| 2013 Q1 | 4.27 Million USD | -24.48% |
| 2013 FY | 5.32 Million USD | -6.07% |
| 2013 Q2 | 3.84 Million USD | -10.19% |
| 2013 Q3 | 7.25 Million USD | 88.76% |
| 2013 Q4 | 5.32 Million USD | -26.63% |
| 2012 FY | 5.66 Million USD | -72.65% |
| 2012 Q4 | 5.66 Million USD | -88.04% |
| 2012 Q3 | 47.34 Million USD | -7.43% |
| 2012 Q2 | 51.14 Million USD | -15.3% |
| 2012 Q1 | 60.38 Million USD | 191.59% |
| 2011 Q4 | 20.71 Million USD | -17.92% |
| 2011 Q1 | 27.67 Million USD | 0.0% |
| 2011 Q3 | 25.23 Million USD | -17.18% |
| 2011 Q2 | 30.46 Million USD | 10.06% |
| 2011 FY | 20.71 Million USD | -30.75% |
| 2010 Q1 | 1.94 Million USD | -14.08% |
| 2010 Q2 | 2.74 Million USD | 40.73% |
| 2010 Q3 | 3.52 Million USD | 28.72% |
| 2010 FY | 29.9 Million USD | 1401.26% |
| 2009 Q2 | 1.99 Million USD | -6.79% |
| 2009 FY | 1.99 Million USD | -30.91% |
| 2009 Q4 | 2.26 Million USD | -3.0% |
| 2009 Q1 | 2.13 Million USD | -13.97% |
| 2009 Q3 | 2.33 Million USD | 17.27% |
| 2008 FY | 2.88 Million USD | -37.29% |
| 2008 Q1 | 2.73 Million USD | -13.67% |
| 2008 Q2 | 2.88 Million USD | 5.45% |
| 2008 Q3 | 2.54 Million USD | -11.86% |
| 2008 Q4 | 2.48 Million USD | -2.24% |
| 2007 Q1 | 2.29 Million USD | -1.04% |
| 2007 Q3 | 4.49 Million USD | -2.26% |
| 2007 FY | 4.59 Million USD | 81.06% |
| 2007 Q4 | 3.16 Million USD | -29.51% |
| 2007 Q2 | 4.59 Million USD | 100.48% |
| 2006 Q2 | 2.53 Million USD | 49.62% |
| 2006 FY | 2.53 Million USD | 192.17% |
| 2006 Q4 | 2.31 Million USD | 8.22% |
| 2006 Q1 | 1.69 Million USD | 24.32% |
| 2006 Q3 | 2.14 Million USD | -15.68% |
| 2005 Q4 | 1.36 Million USD | 4.28% |
| 2005 Q1 | 801 Thousand USD | 16.09% |
| 2005 Q2 | 869 Thousand USD | 8.49% |
| 2005 Q3 | 1.3 Million USD | 50.63% |
| 2005 FY | 869 Thousand USD | 55.73% |
| 2004 Q2 | 558 Thousand USD | 2.39% |
| 2004 Q4 | 690 Thousand USD | -11.42% |
| 2004 Q1 | 545 Thousand USD | -2.15% |
| 2004 FY | 558 Thousand USD | -3.79% |
| 2004 Q3 | 779 Thousand USD | 39.61% |
| 2003 Q4 | 557 Thousand USD | -13.37% |
| 2003 FY | 580 Thousand USD | -22.67% |
| 2003 Q3 | 643 Thousand USD | 10.86% |
| 2003 Q2 | 580 Thousand USD | 3.94% |
| 2003 Q1 | 558 Thousand USD | -12.95% |
| 2002 Q1 | 917 Thousand USD | -7.0% |
| 2002 Q4 | 641 Thousand USD | -23.23% |
| 2002 Q3 | 835 Thousand USD | 11.33% |
| 2002 Q2 | 750 Thousand USD | -18.21% |
| 2002 FY | 750 Thousand USD | -25.82% |
| 2001 Q2 | 1.01 Million USD | -3.35% |
| 2001 Q1 | 1.04 Million USD | 31.74% |
| 2001 FY | 1.01 Million USD | 0.9% |
| 2001 Q3 | 876 Thousand USD | -13.35% |
| 2001 Q4 | 986 Thousand USD | 12.56% |
| 2000 Q2 | 1 Million USD | -47.18% |
| 2000 Q1 | 1.89 Million USD | 21.68% |
| 2000 FY | 1 Million USD | -2.62% |
| 2000 Q4 | 794 Thousand USD | -9.77% |
| 2000 Q3 | 880 Thousand USD | -12.18% |
| 1999 Q2 | 1.02 Million USD | -10.91% |
| 1999 FY | 1.02 Million USD | -32.66% |
| 1999 Q3 | 1.25 Million USD | 21.87% |
| 1999 Q4 | 1.55 Million USD | 24.32% |
| 1999 Q1 | 1.15 Million USD | -35.98% |
| 1998 FY | 1.52 Million USD | -15.11% |
| 1998 Q4 | 1.8 Million USD | 16.54% |
| 1998 Q3 | 1.54 Million USD | 1.31% |
| 1998 Q2 | 1.52 Million USD | -49.8% |
| 1998 Q1 | 3.04 Million USD | 45.09% |
| 1997 Q4 | 2.09 Million USD | 12.31% |
| 1997 FY | 1.8 Million USD | -95.01% |
| 1997 Q1 | 2.7 Million USD | 107.69% |
| 1997 Q2 | 1.8 Million USD | -33.33% |
| 1997 Q3 | 1.86 Million USD | 3.78% |
| 1996 Q4 | 1.3 Million USD | 0.0% |
| 1996 Q3 | 1.3 Million USD | 0.0% |
| 1996 FY | 36.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 61.967% |
| Alkermes plc | 933.53 Million USD | 86.32% |
| Agenus Inc. | 462.29 Million USD | 72.376% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.847% |
| Aptorum Group Limited | 5.25 Million USD | -2329.358% |
| Ardelyx, Inc. | 130.76 Million USD | 2.339% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 73.305% |
| Bicycle Therapeutics plc | 224.41 Million USD | 43.094% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 1.924% |
| ChromaDex Corporation | 26.5 Million USD | -381.76% |
| Chimerix, Inc. | 19.74 Million USD | -546.771% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -263.034% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -75.982% |
| CRISPR Therapeutics AG | 346.76 Million USD | 63.173% |
| Precision BioSciences, Inc. | 140.92 Million USD | 9.378% |
| Dyadic International, Inc. | 2.34 Million USD | -5355.961% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -685.249% |
| Fortress Biotech, Inc. | 165.93 Million USD | 23.041% |
| Lantern Pharma Inc. | 2.73 Million USD | -4561.307% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -78.658% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -3519.013% |
| Incyte Corporation | 1.59 Billion USD | 91.98% |
| IO Biotech, Inc. | 17.55 Million USD | -627.415% |
| Jaguar Health, Inc. | 45.86 Million USD | -178.431% |
| Novavax, Inc. | 2.57 Billion USD | 95.035% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -254.166% |
| Opthea Limited | 264.6 Million USD | 51.737% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 2.297% |
| ContextLogic Inc. | 206 Million USD | 38.007% |
| MiMedx Group, Inc. | 96.33 Million USD | -32.57% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -165.93% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -3518.846% |
| NextCure, Inc. | 14.99 Million USD | -751.537% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3059.451% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -1812.61% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -173.23% |
| Vaxcyte, Inc. | 167.44 Million USD | 23.735% |
| PDS Biotechnology Corporation | 33.25 Million USD | -283.97% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 45.707% |
| Pharming Group N.V. | 244.07 Million USD | 47.678% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -971.171% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 0.067% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1832.793% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1832.793% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -54.92% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -1822.4% |
| Acelyrin, Inc. | 86.35 Million USD | -47.887% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -9729.2% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -788.135% |
| Summit Therapeutics Inc. | 125.25 Million USD | -1.954% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1247.241% |
| Senti Biosciences, Inc. | 52.57 Million USD | -142.919% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -85.68% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 15.713% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -6428.885% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -9461.878% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 43.701% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1263.35% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 43.852% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 74.175% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1070.103% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -364.196% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -955.004% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 73.756% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3331.285% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -237.737% |
| MEI Pharma, Inc. | 8.35 Million USD | -1428.486% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -340.134% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 63.259% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 12.452% |
| Fortress Biotech, Inc. | 165.93 Million USD | 23.041% |
| Precigen, Inc. | 41.64 Million USD | -206.659% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -155.768% |
| AlloVir, Inc. | 45.01 Million USD | -183.694% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 2.019% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 7.326% |
| ImmuCell Corporation | 18.81 Million USD | -578.739% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -352.437% |
| Onconetix, Inc. | 23.18 Million USD | -450.906% |
| PureTech Health plc | 125.58 Million USD | -1.69% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1326.872% |
| Elevation Oncology, Inc. | 34.28 Million USD | -272.513% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5123.108% |
| Seer, Inc. | 39.36 Million USD | -224.413% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -106.529% |
| Innoviva, Inc. | 568.55 Million USD | 77.539% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -369.021% |
| ESSA Pharma Inc. | 3.49 Million USD | -3553.86% |
| GlycoMimetics, Inc. | 6.9 Million USD | -1750.241% |
| GT Biopharma, Inc. | 6.63 Million USD | -1825.298% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 51.698% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 53.099% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -51.983% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1206.579% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -370.039% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -3858.896% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -73.119% |
| Aptose Biosciences Inc. | 15.8 Million USD | -707.815% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1056.781% |
| Soligenix, Inc. | 7.27 Million USD | -1655.418% |
| Century Therapeutics, Inc. | 175.94 Million USD | 27.416% |
| Kura Oncology, Inc. | 51.66 Million USD | -147.193% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -5.296% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -2989.886% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -1830.871% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 49.443% |
| Autolus Therapeutics plc | 263.9 Million USD | 51.61% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1118.327% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -43.713% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -172.298% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 63.808% |
| GRI Bio, Inc. | 2.69 Million USD | -4635.076% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -15674.131% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -310.746% |
| IGM Biosciences, Inc. | 220.17 Million USD | 41.999% |
| INmune Bio, Inc. | 18.86 Million USD | -577.049% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 50.208% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -379.341% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4597.79% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -3793.129% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -118.467% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -32.806% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 51.761% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 84.484% |
| Verastem, Inc. | 71.18 Million USD | -79.399% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -159.69% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -231.031% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -160.985% |
| Histogen Inc. | 5.69 Million USD | -2141.618% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -2811.913% |
| Surrozen, Inc. | 8.14 Million USD | -1467.894% |
| Organovo Holdings, Inc. | 2.74 Million USD | -4547.198% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -40588.783% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -127.112% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -673.407% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -149.897% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -15344.293% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -0.773% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1080.968% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 15.365% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -4797.894% |
| Apollomics, Inc. | 14.15 Million USD | -802.318% |
| Amarin Corporation plc | 279.58 Million USD | 54.324% |
| Mesoblast Limited | 188.79 Million USD | 32.359% |
| Turnstone Biologics Corp. | 14.14 Million USD | -802.636% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 29.362% |
| Synaptogenix, Inc. | 5.52 Million USD | -2209.535% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -1820.954% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 24.927% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1392.37% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -7166.73% |
| Exelixis, Inc. | 678.44 Million USD | 81.177% |
| Better Therapeutics, Inc. | 23.84 Million USD | -435.63% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 22.153% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 78.508% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1095.717% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -7765.468% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -228.063% |
| Gritstone bio, Inc. | 125.91 Million USD | -1.418% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -770.162% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2409.616% |
| Avid Bioservices, Inc. | 275.66 Million USD | 53.674% |
| Insmed Incorporated | 1.66 Billion USD | 92.315% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1559.795% |
| MediWound Ltd. | 27.18 Million USD | -369.728% |
| OmniAb, Inc. | 87.4 Million USD | -46.116% |
| Alector, Inc. | 487.66 Million USD | 73.813% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 68.347% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -593.107% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -232.799% |
| Zai Lab Limited | 240.17 Million USD | 46.829% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 79.731% |
| Aura Biosciences, Inc. | 29.22 Million USD | -336.942% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -34.317% |
| Immunic, Inc. | 25.36 Million USD | -403.41% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -84.449% |
| Veracyte, Inc. | 93.71 Million USD | -36.264% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -4780.434% |
| FibroGen, Inc. | 585.72 Million USD | 78.197% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -634.655% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -19454.386% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2158.084% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.332% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1457.758% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -51.99% |
| TG Therapeutics, Inc. | 169.08 Million USD | 24.473% |
| Galecto, Inc. | 5.89 Million USD | -2065.96% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1441.586% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 95.123% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -343.082% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -911.845% |
| XBiotech Inc. | 8.39 Million USD | -1420.841% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -770.162% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -140.137% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 64.83% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -375.022% |
| Theravance Biopharma, Inc. | 169 Million USD | 24.437% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 89.494% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 74.481% |
| Vaxxinity, Inc. | 30.94 Million USD | -312.697% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 86.868% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2017.439% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 82.864% |
| NexImmune, Inc. | 5.08 Million USD | -2411.785% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -34285.316% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4053.213% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.203% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2377.77% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1613.141% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -385.681% |
| Ainos, Inc. | 7.39 Million USD | -1627.092% |
| Pluri Inc. | 34.11 Million USD | -274.37% |
| Prothena Corporation plc | 135.01 Million USD | 5.416% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 47.469% |
| Celularity Inc. | 102.92 Million USD | -24.071% |
| Rallybio Corporation | 9.43 Million USD | -1253.381% |
| Cue Biopharma, Inc. | 24.44 Million USD | -422.418% |
| MeiraGTx Holdings plc | 319.99 Million USD | 60.091% |
| Omeros Corporation | 403.25 Million USD | 68.331% |
| Humacyte, Inc. | 114.67 Million USD | -11.361% |
| Immunocore Holdings plc | 228.15 Million USD | 44.028% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2519.59% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -66.413% |
| Blueprint Medicines Corporation | 918.64 Million USD | 86.098% |
| CalciMedica, Inc. | 4.02 Million USD | -3070.432% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -631.75% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 17.152% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -48.811% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 54.029% |
| Pulmatrix, Inc. | 15.96 Million USD | -700.006% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -709.643% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -418.999% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 49.083% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -151.457% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 89.451% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -301.803% |
| Nutriband Inc. | 1.07 Million USD | -11736.384% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1101.025% |
| Vor Biopharma Inc. | 59.1 Million USD | -116.068% |
| Roivant Sciences Ltd. | 773.95 Million USD | 83.5% |
| Evogene Ltd. | 17.99 Million USD | -609.867% |
| ProKidney Corp. | 29.21 Million USD | -337.106% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -77.42% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -18014.621% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 93.239% |
| CorMedix Inc. | 11.91 Million USD | -971.573% |
| BioLineRx Ltd. | 50.7 Million USD | -151.874% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 14.555% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -44.396% |
| Atai Life Sciences N.V. | 49.16 Million USD | -159.764% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -309.938% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -610.973% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -2.462% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2158.666% |
| MediciNova, Inc. | 3.89 Million USD | -3181.595% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -598.643% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8389.664% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3528.106% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 67.853% |
| Biomea Fusion, Inc. | 30.69 Million USD | -316.113% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 95.308% |
| Mereo BioPharma Group plc | 15.96 Million USD | -700.056% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -309.298% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -117.615% |
| Absci Corporation | 58.3 Million USD | -119.033% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -570.438% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -298.306% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -73.065% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -45.977% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -278.161% |
| Allakos Inc. | 74.79 Million USD | -70.745% |
| Imunon, Inc. | 8.53 Million USD | -1397.053% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -467.553% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -11.23% |
| BioAtla, Inc. | 48.98 Million USD | -160.697% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1095.717% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -4495.358% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 2.22% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -798.382% |
| XOMA Corporation | 145.58 Million USD | 12.278% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -279.341% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -85.728% |
| aTyr Pharma, Inc. | 31.59 Million USD | -304.168% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -106.566% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -184.01% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -163.842% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4349.652% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1465.392% |
| Akari Therapeutics, Plc | 4.58 Million USD | -2685.886% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -620.149% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 92.258% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -31517.349% |
| UroGen Pharma Ltd. | 243.52 Million USD | 47.559% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 60.227% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -4524.382% |
| Orgenesis Inc. | 35.53 Million USD | -259.378% |
| Entera Bio Ltd. | 1.37 Million USD | -9160.696% |
| GH Research PLC | 6.7 Million USD | -1805.76% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -1778.015% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -578.344% |
| Xencor, Inc. | 283.55 Million USD | 54.964% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4177.257% |
| Replimune Group, Inc. | 113.21 Million USD | -12.8% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3299.009% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -23.351% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -31517.349% |
| Portage Biotech Inc. | 4.45 Million USD | -2769.775% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8389.664% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -454.035% |
| OncoCyte Corporation | 49.29 Million USD | -159.047% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -2987.044% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -15913.487% |
| Purple Biotech Ltd. | 10 Million USD | -1176.412% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2107.138% |
| scPharmaceuticals Inc. | 57.26 Million USD | -123.023% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -930.875% |
| HilleVax, Inc. | 78.9 Million USD | -61.838% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2428.812% |
| Tharimmune, Inc. | 1.81 Million USD | -6935.91% |
| Genprex, Inc. | 3.25 Million USD | -3824.304% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -370.906% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2338.98% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -61892.718% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -35517.267% |
| OKYO Pharma Limited | 7.42 Million USD | -1620.895% |
| Savara Inc. | 37.19 Million USD | -243.367% |
| Curis, Inc. | 57.61 Million USD | -121.664% |
| Daré Bioscience, Inc. | 26.32 Million USD | -385.02% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -225.78% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -8743.837% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -513.406% |
| BeiGene, Ltd. | 2.23 Billion USD | 94.283% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -499.841% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 51.331% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -500.287% |
| Erasca, Inc. | 78.61 Million USD | -62.452% |
| bluebird bio, Inc. | 424.62 Million USD | 69.925% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -19389.448% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 93.243% |
| DBV Technologies S.A. | 42.8 Million USD | -198.376% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -19389.448% |
| Moderna, Inc. | 4.57 Billion USD | 97.207% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1725.661% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -7611.655% |
| Molecular Templates, Inc. | 31.17 Million USD | -309.692% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -648.125% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 78.285% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -2.57% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -365.448% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -250.299% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -129.541% |
| MacroGenics, Inc. | 154.2 Million USD | 17.186% |
| RenovoRx, Inc. | 4.46 Million USD | -2759.494% |
| Adicet Bio, Inc. | 37.12 Million USD | -244.033% |
| Prime Medicine, Inc. | 60.78 Million USD | -110.11% |
| Aditxt, Inc. | 28.53 Million USD | -347.592% |
| Adagene Inc. | 45.16 Million USD | -182.725% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -70571.994% |
| Quantum-Si incorporated | 26.63 Million USD | -379.535% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 81.693% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4097.456% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -11.085% |
| SciSparc Ltd. | 1.59 Million USD | -7906.583% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2194.833% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -49.611% |
| Generation Bio Co. | 171.63 Million USD | 25.593% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1005.671% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -205.288% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 49.463% |
| Invivyd, Inc. | 51.71 Million USD | -146.95% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -38.844% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1863.106% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -69.155% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -12407.835% |
| 2seventy bio, Inc. | 310.12 Million USD | 58.822% |
| ADMA Biologics, Inc. | 193.97 Million USD | 34.165% |
| Clene Inc. | 38.95 Million USD | -227.861% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -253.432% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 50.305% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3528.106% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 32.88% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -948.51% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 35.607% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -947.209% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -165.438% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -141.678% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 65.472% |
| Evaxion Biotech A/S | 17.61 Million USD | -624.877% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 20.645% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 16.634% |
| Trevena, Inc. | 48.26 Million USD | -164.608% |
| Surrozen, Inc. | 8.14 Million USD | -1467.894% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -491.364% |
| Cingulate Inc. | 10.36 Million USD | -1132.571% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -4543.818% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -242.446% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3460.694% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -871.141% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 59.74% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -413.924% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3437.527% |
| Kronos Bio, Inc. | 54.2 Million USD | -135.614% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -171.464% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -461.101% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -536.266% |
| Statera Biopharma, Inc. | 22.67 Million USD | -463.161% |
| ImmunityBio, Inc. | 1.09 Billion USD | 88.288% |
| Korro Bio, Inc. | 51.75 Million USD | -146.763% |
| Kineta, Inc. | 7.22 Million USD | -1668.277% |
| BioVie Inc. | 9.7 Million USD | -1216.257% |
| Codexis, Inc. | 49.94 Million USD | -155.686% |
| Celularity Inc. | 102.92 Million USD | -24.071% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -32.685% |
| Celcuity Inc. | 51.45 Million USD | -148.211% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -36895.139% |
| Cibus, Inc. | 206.11 Million USD | 38.042% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -200.659% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -384.851% |
| IN8bio, Inc. | 8.77 Million USD | -1355.825% |
| Kodiak Sciences Inc. | 213.59 Million USD | 40.21% |
| Annexon, Inc. | 47.11 Million USD | -171.032% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -42.622% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -32.513% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -832.902% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 95.095% |
| Eyenovia, Inc. | 19.78 Million USD | -545.618% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 27.885% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1562.609% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -429.918% |
| Arcellx, Inc. | 339.75 Million USD | 62.412% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -973.332% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 47.99% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1235.407% |
| Moolec Science SA | 13.94 Million USD | -815.753% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -195.942% |
| Geron Corporation | 146.12 Million USD | 12.607% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -152.721% |
| Royalty Pharma plc | 6.29 Billion USD | 97.972% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -221.06% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -43277.173% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5090.665% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 32.487% |
| Humacyte, Inc. | 114.67 Million USD | -11.361% |
| Structure Therapeutics Inc. | 29.05 Million USD | -339.589% |
| 89bio, Inc. | 59.96 Million USD | -112.973% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -382.579% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -10577.676% |
| Genelux Corporation | 8.42 Million USD | -1416.686% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -1762.675% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 6.319% |
| Notable Labs, Ltd. | 4.42 Million USD | -2784.685% |
| Liquidia Corporation | 73.13 Million USD | -74.608% |
| Mustang Bio, Inc. | 17.61 Million USD | -624.814% |
| Immunovant, Inc. | 48.95 Million USD | -160.862% |
| Quantum-Si incorporated | 26.63 Million USD | -379.535% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -232.712% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4015.533% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -72.899% |
| Acasti Pharma Inc. | 11.55 Million USD | -1005.001% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -464.873% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4597.79% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -246.3% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -9270.492% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -1994.898% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -414.214% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -450.832% |
| PepGen Inc. | 34.63 Million USD | -268.759% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -951.589% |
| United Therapeutics Corporation | 1.18 Billion USD | 89.198% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1728.537% |
| Solid Biosciences Inc. | 38.45 Million USD | -232.064% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1392.37% |
| Immuneering Corporation | 12 Million USD | -963.468% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -40588.783% |
| Silo Pharma, Inc. | 1.56 Million USD | -8037.86% |
| Belite Bio, Inc | 4.21 Million USD | -2932.653% |
| XOMA Corporation | 145.58 Million USD | 12.278% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5159.679% |
| Bionomics Limited | 10.15 Million USD | -1157.097% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -494.225% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -457.347% |
| uniQure N.V. | 624.01 Million USD | 79.535% |
| Cassava Sciences, Inc. | 14.19 Million USD | -799.648% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -70571.994% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 24.961% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3383.497% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -48907.418% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -1792.767% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1562.609% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -634.655% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1108.412% |
| Altimmune, Inc. | 16.54 Million USD | -672.051% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 79.326% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -457.347% |
| Compugen Ltd. | 55.77 Million USD | -128.965% |
| Peak Bio, Inc. | 20.75 Million USD | -515.346% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -15.609% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2473.66% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 19.094% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -69.879% |
| Zura Bio Limited | 21.29 Million USD | -499.779% |
| PolyPid Ltd. | 17.46 Million USD | -631.08% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -13.618% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -69.879% |
| Instil Bio, Inc. | 99.8 Million USD | -27.96% |
| argenx SE | 444.95 Million USD | 71.299% |
| Immunome, Inc. | 28.65 Million USD | -345.617% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1431.786% |
| Verona Pharma plc | 58.84 Million USD | -117.034% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -782.367% |
| Shattuck Labs, Inc. | 14.85 Million USD | -759.445% |
| CervoMed Inc. | 2.59 Million USD | -4819.778% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2520.127% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -902.709% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1112.197% |
| Moolec Science SA | 13.94 Million USD | -815.753% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -5349.319% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -129.705% |
| AnaptysBio, Inc. | 364.28 Million USD | 64.944% |
| Design Therapeutics, Inc. | 11.95 Million USD | -968.125% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -906.82% |
| NeurAxis, Inc. | 1.91 Million USD | -6576.551% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -228.054% |
| Lumos Pharma, Inc. | 13.33 Million USD | -857.811% |
| Achilles Therapeutics plc | 19.08 Million USD | -569.068% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -782.367% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2270.522% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -441.398% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -461.101% |
| Nutriband Inc. | 1.07 Million USD | -11736.384% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -317.364% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -780.057% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 68.175% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -293.265% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -878.65% |
| Palisade Bio, Inc. | 2.73 Million USD | -4562.468% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2331.087% |
| Beam Therapeutics Inc. | 478.38 Million USD | 73.305% |
| Neurogene Inc. | 36.54 Million USD | -249.408% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 67.909% |
| AEON Biopharma, Inc. | 159.88 Million USD | 20.129% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -168.006% |
| Sesen Bio, Inc. | 30.98 Million USD | -312.164% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -391.911% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1579.839% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 34.757% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 33.507% |
| Athira Pharma, Inc. | 30.05 Million USD | -324.876% |
| Vaccinex, Inc. | 5.94 Million USD | -2049.192% |
| HCW Biologics Inc. | 15.05 Million USD | -748.429% |
| XOMA Corporation | 145.58 Million USD | 12.278% |
| Nektar Therapeutics | 267.04 Million USD | 52.179% |
| Arvinas, Inc. | 644.6 Million USD | 80.188% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -620.149% |
| Merus N.V. | 102.15 Million USD | -25.016% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 12.74% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -34.257% |
| Rezolute, Inc. | 11.73 Million USD | -988.333% |
| Clene Inc. | 38.95 Million USD | -227.861% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -4385.0% |
| BeyondSpring Inc. | 48.26 Million USD | -164.569% |
| Synlogic, Inc. | 32.89 Million USD | -288.22% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -773.914% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -7715.483% |
| Peak Bio, Inc. | 20.75 Million USD | -515.346% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -101.24% |
| Krystal Biotech, Inc. | 39.71 Million USD | -221.562% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 66.094% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -28.258% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -29411.746% |
| MannKind Corporation | 721.36 Million USD | 82.297% |
| Ikena Oncology, Inc. | 22.33 Million USD | -471.771% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6022.004% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -24.481% |
| Gossamer Bio, Inc. | 249.14 Million USD | 48.743% |
| CohBar, Inc. | 1.03 Million USD | -12254.906% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1094.733% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -570.438% |
| Legend Biotech Corporation | 589.93 Million USD | 78.353% |
| Mural Oncology plc | 37.92 Million USD | -236.704% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 3.718% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -5463.683% |
| Disc Medicine, Inc. | 22.87 Million USD | -458.273% |
| Champions Oncology, Inc. | 28.03 Million USD | -355.52% |
| REGENXBIO Inc. | 262.22 Million USD | 51.3% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -3701.477% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -918.869% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -850.778% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -502.24% |
| Vaxart, Inc. | 34.02 Million USD | -275.327% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -526.335% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -347.587% |
| Cellectis S.A. | 249.57 Million USD | 48.831% |
| Longeveron Inc. | 5.33 Million USD | -2292.824% |
| Repare Therapeutics Inc. | 41.81 Million USD | -205.376% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 94.691% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -111.544% |
| Revolution Medicines, Inc. | 262.39 Million USD | 51.331% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -5960.987% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1380.466% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -982.154% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -809.385% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -5837.006% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.52% |
| Denali Therapeutics Inc. | 122.96 Million USD | -3.856% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2194.833% |
| Veru Inc. | 32.81 Million USD | -289.194% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -1759.15% |
| Cingulate Inc. | 10.36 Million USD | -1132.571% |
| Passage Bio, Inc. | 39.26 Million USD | -225.264% |
| Context Therapeutics Inc. | 4.19 Million USD | -2946.605% |
| Exicure, Inc. | 8.54 Million USD | -1393.8% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -332.781% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1117.862% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -479.397% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 21.647% |
| Nuvalent, Inc. | 31.82 Million USD | -301.298% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -1907.427% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -102.636% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -609.472% |
| OmniAb, Inc. | 87.4 Million USD | -46.116% |
| Anew Medical, Inc. | 8.24 Million USD | -1449.48% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -233.528% |
| Lipocine Inc. | 2.63 Million USD | -4752.698% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -386.088% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -217.579% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -379.341% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -48.229% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2264.47% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -54.332% |
| Ocugen, Inc. | 23.98 Million USD | -432.481% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -175.185% |
| Q32 Bio Inc. | 233.12 Million USD | 45.221% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1308.615% |
| Alumis Inc. Common Stock | 53.5 Million USD | -138.692% |
| Equillium, Inc. | 27.95 Million USD | -356.791% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 38.185% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2169.639% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -1982.271% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 18.828% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -83.926% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1180.353% |
| Dominari Holdings Inc. | 4.63 Million USD | -2655.232% |
| Edesa Biotech, Inc. | 1.84 Million USD | -6834.32% |
| vTv Therapeutics Inc. | 29.56 Million USD | -331.917% |
| Bio-Techne Corporation | 744.34 Million USD | 82.843% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1.274% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 62.926% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -214.738% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -341.016% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -38.269% |
| Nkarta, Inc. | 105.6 Million USD | -20.933% |
| BioCardia, Inc. | 4.59 Million USD | -2682.244% |
| Iterum Therapeutics plc | 32.66 Million USD | -290.99% |